More on DRTSW

- Summary
- Chart
- Profile
- Historical

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

(NQ:DRTSW)
Delayed: 1.96 -0.02 (1.01%)
Prev. Close $1.98  
Open$2.14 
52 Wk High$ 
52 Wk Low$ 
Day High$2.14 
Day Low$1.81 
P/E N/A  
EPS$ 
Volume16,859 

Friends, Peers and Foes (?): DRTS (more...)

May 18, 2026 04:01 PM Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update
May 18, 2026 08:30 AM Alpha Tau to Participate in May Investor Conferences
May 11, 2026 07:01 AM Alpha Tau reports interim brain cancer trial results in 3 patients
May 11, 2026 07:00 AM Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Ob
May 8, 2026 09:10 AM Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma
May 8, 2026 09:00 AM Alpha Tau completes enrollment in pivotal skin cancer trial
May 8, 2026 09:00 AM Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma
May 7, 2026 09:00 AM Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Italy with Alpha DaRT® at the University of Verona’s Pancreas Institute
May 5, 2026 09:15 AM Alpha Tau to present head and neck cancer study at AHNS conference
May 5, 2026 09:14 AM Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer Combination with Pembro
View All Articles

Entities mentioned with DRTSW

View All Entities